Mirtazapine (Avanza, Mirtazon) — patient guide

This page is about mirtazapine — brand names Avanza, Avanza SolTab, Mirtazon, Axit and unbranded generics. The first thing to know about mirtazapine is what it is NOT: it is not an SSRI and it is not an SNRI. It is a NaSSA — a different mechanism, with a different side-effect profile, and a different reason your prescriber chose it.

Two things are true at the same time. Many people on mirtazapine were put on it for a thoughtful reason — depression with collapsing sleep, weight loss, intolerable sexual side effects on an SSRI, or a palliative-care or geriatric setting where the sedation and appetite stimulation are the actual goal. Other people landed on it after a short consult that did not name the trade-offs clearly. Both stories are real. What follows is the longer version of the conversation.

---

Find your medicine

Generic name	Common brand names	Strengths	How often
Mirtazapine	Avanza, Mirtazon, Axit, generics	15 / 30 / 45 mg	Once daily at night
Mirtazapine orodispersible	Avanza SolTab	15 / 30 / 45 mg	Once daily at night

About the SolTab. The orally disintegrating tablet dissolves on the tongue without water. Same dose strengths, same active drug — purely a delivery convenience. Useful when swallowing is difficult, nausea is dominant, or in palliative care.

Closely related medicines you might be on instead. The SSRIs and SNRIs (sertraline, escitalopram, venlafaxine, duloxetine and others) are the more common starting point for depression — mirtazapine is often the alternative when sedation, weight gain, or avoidance of SSRI sexual side effects is wanted. Older tricyclic antidepressants share some of mirtazapine’s sedation and weight profile and remain in use, particularly for chronic pain. For short-term sleep, benzodiazepines and Z-drugs are a contrasting class — different mechanism, dependence concerns, generally short-term-only.

---

This is not an SSRI — what mirtazapine actually is

Most patients arrive at this page thinking mirtazapine is an SSRI. It is worth correcting that, because the side-effect profile is genuinely different and the conversation makes more sense with the mechanism named.

Mirtazapine is a NaSSA — Noradrenergic and Specific Serotonergic Antidepressant. It does four things at once at the receptor level:

• Alpha-2 adrenergic antagonism — blocks the brake on noradrenaline release, so more noradrenaline and serotonin reach the synapse.
• 5-HT2 antagonism — blocks one branch of serotonin signalling that is associated with anxiety and sexual side effects on the SSRIs.
• 5-HT3 antagonism — blocks the serotonin receptor that drives nausea. Mirtazapine is mildly antiemetic; SSRIs are pro-nauseating.
• H1 antihistamine effect — drives sedation and appetite stimulation.

The practical consequence: lower rates of sexual side effects than SSRIs, less nausea, more sedation, more appetite stimulation, and a different list of things to watch for. It does NOT share the GI-bleeding signal of the SSRIs. It does carry its own distinct watch-list — weight gain, sedation, rare agranulocytosis, hyponatraemia, restlessness — covered below. See the eTG Psychotropic chapter and AMH for the canonical AU framing.

---

What it treats

On-label in AU. Mirtazapine is TGA-registered for major depressive disorder in adults. That is the only indication on the AU label.

Off-label uses that are legitimate and mainstream in their respective specialties. Each of these is supported by published evidence and used by the specialty that owns the indication, but is NOT TGA-approved in AU and is not a self-initiated choice — the prescriber (often a sleep physician, geriatrician, oncologist, palliative-care physician or psychiatrist) will discuss the risks and benefits if mirtazapine is being considered for one of these:

• Insomnia at low dose (7.5–15 mg nocte). Geriatric medicine and sleep medicine sometimes use low-dose mirtazapine for chronic insomnia when benzodiazepines and Z-drugs are being avoided. The European insomnia guideline (Riemann et al.) discusses the place of mirtazapine in selected patients.
• Appetite stimulation in cancer cachexia, anorexia of chronic illness, and palliative care. Oncology and palliative-care guidance discusses this use — Riechelmann and colleagues summarise the evidence. The H1 and 5-HT2C antagonism drive the appetite effect; useful when depression and weight loss coexist.
• Augmentation of an SSRI or SNRI in treatment-resistant depression. STAR*D level 2 and the RANZCP mood disorders guidance support mirtazapine as an augmentation agent in treatment-resistant depression. Stahl describes the mirtazapine-plus-venlafaxine combination as ‘California rocket fuel’ in his psychopharmacology textbook. This is psychiatry territory — not a GP-initiated combination — because combining serotonergic agents adds serotonergic load.
• Generalised anxiety and PTSD-associated hyperarousal — adjunctive role. Modest evidence, off-label, specialist-led.

The takeaway: if you are on mirtazapine for something other than depression, that is not unusual — but it is worth knowing the use is off-label and the prescriber should have walked through why.

---

The basics

1. Take it at night. Mirtazapine is dosed once daily nocte. The sedation makes daytime dosing impractical for most people.
2. Do not drive or operate machinery until you know how you react. Sedation is heaviest in the first 1–2 weeks at the standard 30 mg dose.
3. Do not self-titrate. The dosing paradox (low dose feeling more sedating than high dose) makes mirtazapine particularly easy to dose wrong on your own. Message the prescriber if the side effects are intolerable.
4. Do not stop suddenly. Discontinuation symptoms are real and prevented by a slow taper.
5. Any unexplained fever, sore throat, mouth ulcers, or signs of infection in the first months — STOP the tablet and contact the prescriber the same day. Rare agranulocytosis is the reason. This counsel is non-negotiable at the start of treatment.
6. Go to ED for sudden severe agitation, fever, shivering, twitchy muscles, heavy sweating, and diarrhoea — these can be signs of serotonin syndrome.
7. For patients under 25 (and parents/carers): weekly check-ins for the first month and a low threshold for an earlier visit. Crisis numbers below.

Everything else — the dosing paradox, the first-month timeline, weight, sedation, sexual effects, the integrative levers, how to stop safely — is below.

---

The dosing paradox — read this carefully

The most counter-intuitive feature of mirtazapine, and the one patients and clinicians most often get wrong:

7.5–15 mg can feel MORE sedating than 30–45 mg.

The reason is that the H1 antihistamine effect that drives sedation is fully recruited at low doses, but the noradrenergic activation that partly counteracts it only kicks in as the dose rises. So:

• 7.5–15 mg nocte — H1 antihistamine + 5-HT2 dominate. Sedation and appetite stimulation lead. Antidepressant effect modest. This is the off-label sleep and appetite dose.
• 30 mg nocte — standard adult antidepressant starting dose. Noradrenergic activation comes in. Many people feel LESS sedated at 30 mg than at 15 mg.
• 45 mg nocte — top of the usual range. Activation fully recruited. Antidepressant effect maximal. Sedation often least.

What this means in practice. If your prescriber starts you at 15 mg and you feel like you cannot get out of bed, the answer is sometimes to go UP, not down. Do not halve the tablet or skip days on your own — that does not give you a gentler version, it just delays the conversation. Message the prescriber. The fix may be a dose increase, not a dose decrease.

Doses above 45 mg are specialist territory and not standard GP practice.

---

What to expect in the first month

Within days

• Sedation. Almost universal. Take it at night. Often improves over 1–2 weeks.
• Appetite increase. Often noticeable in the first week. Carbohydrate and late-night cravings are common.
• Vivid dreams. Common, often settles. Worth warning about, particularly for patients with PTSD.
• Dry mouth and mild dizziness on standing.

Weeks 1–2

• Sedation often settles or shifts as the dose is adjusted upward (the paradox).
• Sleep often improves noticeably; mood has not lifted yet.
• Any unexplained fever, sore throat, or mouth ulcers — stop the tablet and contact the prescriber the same day.

Weeks 2–4

• Mood lift starts. Sleep often shifts first, then mood, then motivation and interest.
• Weight may start to creep up.
• For patients under 25 — weekly review for the early-suicidality window.

Weeks 4–12

• Full antidepressant effect builds.
• Weight gain accrues over the first 3–6 months.
• If nothing has moved at all by week 4, that is information — the prescriber adjusts dose or considers a change.

How long until it works?

Sleep and appetite shift often happen within days. Mood lifts at 2–4 weeks. Full effect builds by 6–12 weeks. Do not take a snapshot at week one and decide the medicine is not working — that is the window when it is least helpful and most disruptive. Equally, do not give up on it at week three because of weight or sedation alone — the antidepressant effect is just emerging at that point, and the trade-off looks different once mood has shifted.

Sick day rules

Unlike blood pressure tablets, you do NOT pause mirtazapine for a stomach bug or fever. The dehydration sick-day rule that applies to ACE inhibitors does not apply here. Take the dose with whatever you can keep down. If you genuinely cannot keep anything down for more than 24 hours, message the prescriber — but the bigger issue is that stopping abruptly causes discontinuation symptoms within days. The one exception to the do-not-pause rule is the agranulocytosis pathway — unexplained fever or sore throat in the first months IS a reason to stop and contact the prescriber same-day.

---

Tap any section below to expand the detail.

How it works

Mirtazapine blocks four receptors at once — alpha-2 adrenergic, 5-HT2, 5-HT3, and H1 histamine. The alpha-2 block lifts the brake on noradrenaline release, so more noradrenaline reaches the synapse; that same alpha-2 receptor also sits on serotonin neurons and lifting it increases serotonin release indirectly. So mirtazapine raises both noradrenaline and serotonin signalling — but it does it by releasing more transmitter rather than blocking reuptake. That is the mechanism that earned it the NaSSA name.

The 5-HT2 block matters because the 5-HT2A and 5-HT2C receptors are the serotonin sub-types most associated with anxiety, sleep disruption, and the sexual side effects of SSRIs. Blocking them downstream while increasing release upstream is part of why mirtazapine’s side-effect profile differs from the SSRIs. The 5-HT3 block is the antiemetic branch — SSRIs activate 5-HT3 and that is part of why they make people nauseated; mirtazapine does the opposite.

The H1 antihistamine effect is the explanation for both the sedation and the appetite stimulation. It is the same receptor that older sedating antihistamines like promethazine and doxylamine block — which is why mirtazapine at 7.5–15 mg feels mechanistically closer to an old-fashioned sedating antihistamine than to an SSRI.

The simple ‘low brain chemical equals depression, top it up and feel better’ story that often gets repeated is incomplete — for any antidepressant. What we actually understand involves slow remodelling of stress circuits, downstream receptor sensitivity changes, and probably effects on neuroplasticity. The drugs take weeks to work, not hours, for this reason.

Side effects in detail

Common and usually settling

• Sedation — almost universal in the first 1–2 weeks at standard dose. Often improves as the dose goes up.
• Increased appetite and weight gain — see dedicated section below.
• Vivid dreams or nightmares — common in the first weeks; usually settles.
• Dry mouth.
• Dizziness on standing (mild orthostatic hypotension).
• Headache in the first days.
• Constipation.

Common and ongoing

• Weight gain — average around 2–5 kg in the first 3–6 months, sometimes more.
• Daytime drowsiness in some people, particularly at 15 mg or in older patients.
• Lower libido or delayed orgasm — uncommon compared with SSRIs but not zero. Worth naming if it appears.

Worth knowing about

• Hyponatraemia (low sodium, SIADH-mediated). Most common in older adults in the first 2–4 weeks (Coupland et al. BMJ 2011). Symptoms — new confusion, lethargy, headache, falls, unsteadiness. The prescriber will usually check sodium 2–4 weeks after starting if you are over 65, on a diuretic, or have lower body mass.
• Restless legs or akathisia — uncommon but documented. New inability to sit still, jiggling legs at night, worsening sleep despite the sedation — contact the prescriber.
• Orthostatic hypotension and falls in older adults — particularly additive with other sedating medicines. Review polypharmacy.
• QT interval prolongation — minor at standard doses; relevant at higher doses, in overdose, or alongside other QT-prolonging drugs. The prescriber may consider an ECG before starting if there is cardiac disease, electrolyte abnormality, or other QT-prolonging medications.
• Mild liver enzyme rise — uncommon. Routine LFT monitoring is not standard, but check if there are symptoms (jaundice, dark urine, RUQ pain, unexplained nausea or fatigue).

Rare but serious — call the prescriber or go to ED

• Agranulocytosis or severe neutropenia. Around 1 in 1000–3000. Any unexplained fever, sore throat, mouth ulcers, or signs of infection in the first months — STOP the tablet, contact the prescriber the same day, urgent FBC. Do not wait. See the TGA product information for the labelled warning.
• Serotonin syndrome. Agitation, fever, shivering, sweating, tremor, twitchy muscles, hyperreflexia, diarrhoea. Most often when mirtazapine is combined with an MAOI, tramadol, triptan, ondansetron, lithium, or St John’s wort. Call 000 or go to ED.
• Sudden severe agitation or new suicidal thoughts, especially in the first 1–4 weeks and particularly in patients under 25. Do not wait — contact the prescriber or call a crisis line.
• Severe rash (especially with mouth ulcers and fever).
• Allergic reaction — facial swelling, breathing difficulty, severe rash.

Weight gain — the honest framing

This is the side effect most patients on mirtazapine ask about, and the one most often soft-pedalled at the initial consult.

The numbers. Average weight gain is around 2–5 kg in the first 3–6 months, with substantial individual variation — some people gain less, some gain more. The signal is most pronounced early and tends to plateau, but it can keep accruing in some people. The mechanism is dual — the drug stimulates appetite directly (H1 and 5-HT2C effects) and tends to shift food preferences toward carbohydrate-rich, energy-dense choices, particularly at night.

Where weight gain is welcome. When depression coexists with weight loss, cancer cachexia, anorexia of chronic illness, or geriatric weight loss, the appetite stimulation is a clinical feature, not a bug. The same receptor profile that makes mirtazapine a difficult choice for some patients makes it a very useful one for these.

Where weight gain is unwelcome. When the starting weight is already a concern — for cardiometabolic, joint, body-image, or activity-related reasons — the weight signal is a real cost to weigh against the antidepressant benefit. Honest framing matters: it is reasonable to ask the prescriber ‘how much weight gain on average’ BEFORE starting, so the conversation is open and not silently distressing at follow-up.

Proactive strategies — softening, not eliminating.

• Resistance training twice or three times a week to preserve lean mass. Walking on its own does not do this.
• Protein-prioritised eating — around 1.2–1.6 g/kg/day for most adults. Protein at the start of meals reduces total intake later.
• Prepared meals — late-night driven eating is a common pattern with mirtazapine. Having a planned light snack ready (Greek yoghurt, a piece of fruit, a small handful of nuts) defuses the trip-to-the-pantry decision.
• Alcohol moderation. Alcohol amplifies the appetite-and-disinhibition trap and disrupts sleep, which both worsen mood and worsen the weight trajectory.
• Regular movement as a daily anchor, not a punishment for the weight.

These strategies meaningfully soften the signal. They do not eliminate it. If the weight trajectory is a hard ‘no’ at 4–6 weeks and the antidepressant effect has not yet justified it, a switch to a different antidepressant is a reasonable conversation. The decision is yours, made with the prescriber.

Sexual side effects — the genuine difference from SSRIs

This is the one place where a comparative claim about mirtazapine is on solid evidence.

The pattern. Mirtazapine has consistently lower rates of sexual side effects than the SSRIs and SNRIs — lower libido, delayed orgasm, erectile changes, reduced genital sensation are all reported less often. This is one of the most common reasons mirtazapine is chosen when an SSRI has been tried and the sexual side effects were the deal-breaker. The 5-HT2 antagonism is the most likely mechanism.

This is not zero. A minority of people on mirtazapine do report sexual changes — lower libido is the most common, and it is sometimes hard to separate from the depression itself. The point is not ‘mirtazapine has no sexual side effects’ (it does, in some people) — it is ‘mirtazapine is a reasonable choice when SSRI sexual side effects have been intolerable’.

The conversation. Discuss baseline sexual function before starting, and bring it up at each review. If you do not raise it, the prescriber may not — and the assumption that absence of mention means absence of problem is wrong as often as it is right.

Drugs, food, and alcohol

Never combine with — serotonin syndrome risk (see eTG Psychotropic and AMH):

• MAOIs. Phenelzine, tranylcypromine, moclobemide, selegiline. Also the antibiotic linezolid (acts as a reversible MAOI) and methylene blue used in some surgeries. 14-day washout in both directions.
• St John’s wort. Both serotonergic (additive serotonin-syndrome risk) and a strong CYP3A4 inducer that reduces mirtazapine levels.
• Tryptophan and 5-HTP at higher doses.
• Recreational MDMA, cocaine, methamphetamine — additive serotonergic and cardiovascular risk. Worth a non-judgmental conversation if this is part of your life.

Use cautiously — discuss with the prescriber first:

• Tramadol, fentanyl, pethidine — additive serotonergic risk (tramadol also lowers seizure threshold).
• Triptans (sumatriptan and others for migraine) — theoretical risk; usually manageable with awareness.
• Ondansetron for nausea — short courses usually fine; flag if both long-term.
• Lithium — serotonergic load increases; monitor lithium level.
• SAMe supplement — additive serotonergic load.
• SSRIs and SNRIs — combination is intentional in psychiatry for treatment-resistant depression but adds serotonergic load. Not a GP-initiated combination.

CNS depressants — additive sedation and falls risk:

• Alcohol — minimise or abstain during titration. Habitual heavy drinking is also independently depressogenic.
• Benzodiazepines and Z-drugs.
• Opioids.
• Sedating antihistamines (promethazine, doxylamine, older over-the-counter cold-and-flu products).
• Gabapentinoids (gabapentin, pregabalin).

Liver enzyme interactions worth knowing about:

• Strong CYP3A4 inhibitors — clarithromycin, erythromycin, ketoconazole, itraconazole, voriconazole, ritonavir. Can raise mirtazapine levels; monitor for sedation, consider dose reduction.
• Strong CYP3A4 inducers — carbamazepine, phenytoin, rifampicin, St John’s wort. Can reduce mirtazapine levels; antidepressant effect may drop.
• Warfarin — case reports of INR rise after starting mirtazapine; check INR after starting or changing dose.

Bone marrow caution:

• Clozapine — case reports of additive bone-marrow suppression risk; specialist-managed combination only with FBC monitoring.

Older-adult caution:

• Diuretics + mirtazapine in older adults — cumulative hyponatraemia risk. Check sodium 2–4 weeks after starting.

Food. No specific food restrictions. Take with food if heartburn or mild nausea is a problem (uncommon).

Caffeine. Minor interaction; excess caffeine can mask the sedation signal and disrupt sleep. Trial reducing intake if sleep stays poor after starting.

Generic substitution at the pharmacy. Generics are bioequivalent — they work the same. If the pharmacist offers a cheaper generic, that is fine.

Monitoring

• Phone or in-person check-in at 1–2 weeks after starting, and again at 4 weeks. Earlier if you are under 25 — usually weekly for the first month in that age group.
• Full blood count — at baseline, and any time unexplained fever, sore throat, mouth ulcers, or signs of infection appear in the first months. Routine FBC monitoring is not standard, but the threshold for an urgent FBC is low.
• Sodium check at 2–4 weeks after starting if you are over 65, on a diuretic, or have lower body mass.
• Weight check at baseline and at each review — to make the conversation visible rather than silent.
• ECG before starting if you have known cardiac disease, electrolyte issues, or are on other QT-prolonging drugs.
• Liver function if symptoms emerge (jaundice, dark urine, RUQ pain, unexplained nausea or fatigue).
• Then every 3–6 months for the first 12 months; longer intervals after that if things are stable.
• Message the prescriber if you start a new medicine (including over-the-counter and supplements), develop new agitation or suicidal thoughts, get unexplained dizziness or unsteadiness, or want to stop.

Stopping or pausing — discontinuation in detail

Discontinuation syndrome is real, even if milder than venlafaxine. When mirtazapine is stopped — particularly suddenly — the nervous system can produce a cluster of symptoms within days:

• Dizziness, unsteadiness.
• Nausea, headache, flu-like feeling.
• Vivid dreams, sleep disruption.
• Irritability, mood swings, returning anxiety or low mood.
• Occasional brain zaps (brief electric-shock sensations, often triggered by eye movements).

These are often mistaken for the depression coming back. They are not relapse; they are the nervous system adjusting. The 2024 Lancet Psychiatry systematic review (Henssler et al.) put the discontinuation conversation on firmer footing — these symptoms are common across antidepressants, real, and meaningfully reduced by slow tapering.

Mirtazapine-specific notes. Mirtazapine’s discontinuation profile is generally milder than venlafaxine or paroxetine but more pronounced than fluoxetine. A reasonable starting plan for most people is a step-down over 2–4 weeks:

• 45 mg to 30 mg for 1–2 weeks.
• 30 mg to 15 mg for 1–2 weeks.
• 15 mg to 7.5 mg (half-tablet) for 1–2 weeks.
• Stop.

For patients who have been on mirtazapine a long time or have struggled with stopping before, slower is better — 4–6 weeks or longer, with smaller decrements at the bottom of the dose. The last few milligrams can be the hardest.

When to do it. Not in the middle of a hard life stretch. Plan for a stable window. Pregnancy, planned surgery, major work transitions, and grief are not the right time.

How long do you stay on? A common course is 6–12 months past full remission for a first episode of depression, then a careful taper with review. For multiple episodes or specific risk patterns, longer is reasonable. The decision is made with the prescriber, based on where you are — not a default rule. See the RANZCP mood disorders guideline and Black Dog Institute resources for the practical tapering frameworks.

Suicidality risk in patients under 25 — what to know

The TGA carries a warning, consistent with the FDA black box, about a small increase in suicidal thoughts and behaviours in patients under 25 in the early weeks of antidepressant treatment — see the TGA notice and NPS MedicineWise. This is an antidepressant class effect, not unique to mirtazapine.

What this means in practice.

• The risk is real but small in absolute terms. Population-level studies have not shown an increase in completed suicide — the signal is in suicidal ideation and self-harm, not death.
• Untreated depression also carries suicide risk. ‘Do not treat’ is not the safer default.
• The most reliable protection is a structured plan — weekly review for the first month, both patient and parent/carer knowing what to watch for, low threshold for an unscheduled visit, crisis numbers easily accessible.

Warning signs that need same-day contact.

• New or worsening agitation.
• New withdrawal from people who matter to them.
• Talk of self-harm, hopelessness, being a burden, wanting to disappear.
• Sleep collapse with significant mood change.
• Giving things away, sudden calm after a period of distress.

Crisis numbers — put these on the fridge.

• Lifeline 13 11 14 (24/7).
• Beyond Blue 1300 22 4636 (24/7).
• Kids Helpline 1800 55 1800 (24/7, ages 5–25).
• Suicide Call Back Service 1300 659 467 (24/7).
• 13YARN 13 92 76 (24/7, for Aboriginal and Torres Strait Islander people).
• 000 for immediate danger.

Mirtazapine in patients under 18. Efficacy data in this age group is weak. Mirtazapine is not a first choice in patients under 18 and is usually specialist-initiated when used.

Pregnancy and breastfeeding

The decision is rarely ‘just stop the medicine’. Both treated and untreated depression carry risk in pregnancy, and the conversation has two sides.

The honest framing. Mirtazapine’s perinatal safety data is more limited than sertraline or escitalopram, both of which have stronger datasets and remain the preferred antidepressants when one is needed in pregnancy. That does not mean mirtazapine is unsafe in pregnancy — it means the evidence base is thinner and the decision is more case-by-case.

If you are planning a pregnancy and doing well on mirtazapine. Tell the prescriber before trying. The conversation usually weighs the strength of the current response against switching to sertraline or escitalopram before conception.

If pregnancy has already happened on mirtazapine. Do not stop abruptly — discontinuation symptoms are real and an unmanaged taper during early pregnancy adds risk. Contact the prescriber urgently and request perinatal psychiatry input. The Royal Women’s Hospital and MotherSafe (NSW) are reasonable AU specialty resources for the prescriber to draw on.

Untreated maternal depression carries its own risks — preterm birth, low birth weight, postnatal depression, impaired bonding. Stopping is not automatically the safer choice.

Late pregnancy. Some neonates have transient adjustment symptoms in the first days after birth. Usually self-limited; the paediatric team is aware.

Breastfeeding. Mirtazapine transfers to breast milk in small amounts. The decision is again case-by-case with specialist input rather than a default ‘stop’.

Cost

Mirtazapine is PBS-listed. Confirm current restriction status (unrestricted versus streamlined Authority for depression) with the prescriber or pharmacist at the time of script.

From 1 January 2026, the PBS co-payment is:

• General patient: up to $25.00 per script.
• Concession card holder: up to $7.70 per script.

Generic versions cost the same as branded ones at PBS pricing and work the same. The actual charge may be lower if the medicine is under co-payment, or higher if a brand with a premium is chosen. Confirm with the pharmacist.

The Avanza SolTab orodispersible formulation is more expensive than the standard tablet and may not be PBS-subsidised at the same tier — check at the pharmacy.

---

The integrative view

Most patients I see want to do everything they reasonably can alongside the medicine. This is the longer version of that conversation. The principle: the medicine is one lever among several. For mild-to-moderate depression and anxiety, the other levers do as much work as the drug. For severe depression, the drug often clears the floor enough that the other levers become possible.

Strong evidence — these reliably help

• Psychotherapy — CBT and interpersonal therapy in particular. For mild-to-moderate depression, therapy is at least as effective as medicine alone and the benefits last longer after stopping. For moderate-to-severe depression, the combination of medicine and therapy outperforms either alone. Medicare rebates apply to a limited number of sessions under a Mental Health Treatment Plan. If the medicine is the only lever, that is doing less than half the available work.
• Aerobic exercise. The Cochrane review (Cooney et al.) showed exercise has a measurable antidepressant effect; in some studies effect sizes were comparable to medication in mild-to-moderate depression. 150 minutes/week of brisk walking, cycling, swimming or equivalent. Compounds with medication.
• Resistance training 2–3 sessions a week. Particularly relevant on mirtazapine because it preserves lean mass against the weight signal.
• Sleep regularisation. Disrupted sleep both causes and worsens depression. Consistent sleep and wake times, dark cool room, screens out of bed, morning light exposure. If you snore, have witnessed pauses in breathing, or are tired despite enough time in bed — get a sleep study. Treating obstructive sleep apnoea is a depression intervention.
• Reducing alcohol. Regular drinking worsens depression and anxiety over time, disrupts sleep architecture, and undermines the work the medicine is doing. On mirtazapine, alcohol also amplifies sedation and the late-night appetite trap.
• Mediterranean-pattern eating — the SMILES trial (Jacka 2017) showed a Mediterranean dietary intervention as an add-on to usual care had a meaningful effect on depression. Particularly relevant on mirtazapine because the dietary pattern supports the proactive weight-management strategy at the same time.
• Social connection. Loneliness behaves like a clinical risk factor in its own right. One sustained connection that feels real does more than ten low-quality ones.

Moderate evidence — likely helpful

• Mindfulness-Based Cognitive Therapy (MBCT) — Cochrane-level evidence for preventing relapse in recurrent depression. Particularly relevant if there has been more than one episode.
• Omega-3 (EPA-predominant), 1–2 g EPA/day — meta-analyses show a small adjunctive effect. EPA:DHA ratio above 60:40. Flag if also on blood thinners.
• Bright light therapy — strong evidence in seasonal-pattern depression; modest evidence in non-seasonal depression.
• Vitamin D — correct to a level of 75–100 nmol/L if low. General health benefit; mood effect modest in isolation.
• Magnesium — small RCT signal in mild-to-moderate depression. Food first.

Limited but worth knowing

• L-methylfolate 7.5–15 mg/day — adjunctive evidence in partial responders, particularly with low or borderline folate or known MTHFR variants. Mixed RCT data; reasonable trial in the right context, discussed with the prescriber.
• SAMe — modest standalone evidence. Combining with mirtazapine adds serotonergic load. Discuss before starting.

Avoid alongside mirtazapine

• St John’s wort — both serotonergic (additive serotonin-syndrome risk) and a strong CYP3A4 inducer that reduces mirtazapine levels.
• 5-HTP and tryptophan supplements at higher doses — additive serotonergic risk.
• Melatonin routinely — mirtazapine itself is sedating, so adding melatonin nightly adds to morning sedation. Use only as needed for circadian shift.

Weight management — proactive from day 1

Because the weight signal is predictable, the proactive plan is part of starting mirtazapine, not a reaction to it.

• Resistance training twice or three times a week — preserves lean mass.
• Protein-prioritised eating at around 1.2–1.6 g/kg/day for most adults — supports satiety and lean mass.
• Prepared light evening snack ready to defuse the late-night driven-eating trap.
• Alcohol moderation — amplifies the appetite-and-disinhibition pattern.
• Daily walk or movement anchor — not a punishment for the weight, just a baseline.
• Honest weight conversation at each review — the silent version of this is the one that erodes the doctor-patient relationship.

These soften the signal. They do not eliminate it. The decision to continue, switch, or accept the trade-off is yours, made with the prescriber.

A note on the ‘anti-antidepressant’ online conversation

There is a real online conversation that says antidepressants are over-prescribed and harmful — and a real online conversation that says they are lifesaving and under-used. Both stories contain truth and both contain distortion. The discontinuation syndrome is real and was minimised for years. The drugs also keep many people alive who would not be without them. Hold both. The most useful position is neither for nor against — it is a clear-eyed conversation about whether this particular drug, at this particular dose, is fitting you, and the willingness to change course when it is not.

---

Track these between now and your next visit

• Mood, sleep, energy, anxiety — a brief daily note (one or two words) is enough. Patterns matter more than single days.
• Weight — weekly is enough. The point is visibility, not vigilance.
• Appetite and food pattern — particularly late-night eating.
• Sedation pattern — when it hits, when it lifts, whether it is settling.
• Any fever, sore throat, mouth ulcers, or signs of infection — same-day contact.
• For patients under 25 (and parents/carers) — any new agitation, withdrawal, talk of self-harm, sleep collapse — contact same day.
• Anything else started — over the counter, supplements, herbal products.

Bring the list to the review.

---

This is general information, not personal medical advice. Every patient is different. Decisions about your medicines — which one, what dose, when to stop, what to combine with — are made with the doctor who prescribed them. If anything on this page appears to contradict advice from your treating doctor, follow your doctor; they have context about your situation that this page cannot.

Reading this page does not establish a doctor-patient relationship with Dr Hoebing Lo. If you are not a current patient, please discuss your medicines with your own GP, specialist, or pharmacist.

About the integrative content. The lifestyle, dietary, therapy and complementary recommendations on this page summarise current published research. Effect sizes are approximations from clinical studies — your individual response will vary, and real-world results are commonly smaller than trial results because day-to-day life differs from study conditions. Supplements and herbal products are not interchangeable with prescribed medication and can interact with it. Talk to your doctor and pharmacist before starting any new supplement, herbal product, or significant change in diet.

Off-label uses noted on this page (mirtazapine for insomnia, for appetite stimulation in cachexia, for SSRI/SNRI augmentation, for anxiety and PTSD adjunct) are not TGA-approved indications in Australia. They are described because they are legitimate and mainstream in their respective specialties (sleep medicine, geriatric medicine, oncology, palliative care, psychiatry). They are not self-initiated choices — these uses are prescriber-led after a specialist or GP-with-special-interest conversation about the risk and benefit for the individual patient.

Mental-health crisis. If you are in immediate danger or thinking about ending your life, call 000, go to your nearest emergency department, or call Lifeline 13 11 14, Beyond Blue 1300 22 4636, Kids Helpline 1800 55 1800, Suicide Call Back Service 1300 659 467, or 13YARN 13 92 76. All of these are free, confidential and available 24 hours a day.

Currency. This page reflects clinical practice as of the last-reviewed date. Medicine evolves; specific details may date between reviews. Pricing shown is indicative; confirm with your pharmacist.

No commercial relationships. Dr Hoebing Lo has no financial or commercial relationship with the manufacturer of any medicine, brand, or supplement mentioned on this page.

Emergencies. If you have sudden severe agitation with fever, shivering and twitchy muscles (possible serotonin syndrome); unexplained fever, sore throat or mouth ulcers in the first months of mirtazapine treatment (possible agranulocytosis); facial swelling or breathing difficulty; or signs of significant bleeding, call 000 or go to your nearest emergency department. Do not wait, and do not message us first.